Inventiva S.A. (IVA)

Pharmaceutical Preparations · market cap $665M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Inventiva S.A. (IVA) is a small French pharmaceutical company (~84 employees, ~$690M market cap) whose lead asset IVA337 is in Phase 3 development for NASH (nonalcoholic steatohepatitis). The company also has Odiparcil in Phase 2 for Mucopolysaccharidosis VI, but the near-term investment case hinges almost entirely on two upcoming Phase 3 IVA337 readouts estimated for December 2026 and June 2027.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
IVA337	Phase 3	NASH - Nonalcoholic Steatohepatitis
Odiparcil	Phase 2	Mucopolysaccharidosis VI

Price & technical context

3-month

+0.0%

6-month

-33.5%

12-month

-37.1%

52-wk range

$3.26–$7.15

vs 50-day MA

-15.4%

vs 200-day MA

-26.7%

Realized vol

78.7%

Max drawdown

-54.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for IVA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.